FURVENT Misses Its Central Review Endpoint

Company ArriVent BioPharma; Shanghai Allist Pharmaceuticals Event Type Phase 3 topline result (primary endpoint missed) Modality Small molecule (oral EGFR tyrosine-kinase inhibitor) Asset Firmonertinib Target EGFR exon 20 insertion mutations Disease Area EGFR exon 20 insertion non-small-cell lung cancer (first line) Summary ArriVent and its…